Autoimmunity BioSolutions Expands Leadership Team
Autoimmunity BioSolutions (ABS) is recognized for its innovative contribution to the field of autoimmune therapy, particularly with its personalized, genetically guided immuno-corrective treatment aimed at addressing elevated levels of soluble IL7 receptor (sIL7R). This cutting-edge approach is designed to rectify the therapeutic responses observed in autoimmune conditions.
Leadership Appointments to Drive Strategic Vision
Recently, ABS made significant strides by appointing key figures to its executive team. Richard Polisson, MD, MHSc, steps in as Chief Medical Officer, bringing a wealth of expertise from his tenure at Sanofi-Genzyme, where he was pivotal in advancing therapeutic programs across various clinical landscapes. His background as a Rheumatologist and his academic role at Mass General Hospital and Harvard Medical School underscore his deep clinical knowledge.
Alongside him, Jen Beachell, MBA, has been appointed as Chief Business Officer. She previously played a crucial role in the commercial landscape of autoimmune diseases at Johnson & Johnson, showing her capability to lead business strategies in this complex sector. The addition of Alidad Mireskandari, PhD, as the Scientific Advisor of Diagnostics and Robert McBurney, PhD, as Director of Personalized Medicine Strategy further solidifies ABS's commitment to addressing the unmet needs within this therapeutic space.
Addressing Unmet Needs in Autoimmune Disease
ABS is tackling a critical issue in autoimmune diseases, particularly concerning the poor responses related to standard treatments. Scientific studies have unveiled a prevalent single nucleotide polymorphism (SNP) linked to an increase in circulating sIL7R levels, which correlates with heightened disease severity and resistance to conventional therapies. Many patients undergoing treatment for conditions such as rheumatoid arthritis (RA), lupus nephritis (LN), and type 1 diabetes (T1D) experience over a fifty percent non-response rate, highlighting the urgent need for more effective solutions.
For instance, research has illustrated a strong link between high sIL7R levels and inadequate responses to treatments like infliximab. This crucial relationship points to the potential of ABS's therapy in enhancing treatment efficacy by normalizing sIL7R levels in genetically predisposed patients.
Research and Development Strategy for Enhanced Outcomes
ABS is moving forward with patient bio-sample studies that aim to refine the success rates of Proof-of-Concept (POC) clinical trials. The initial focus will be on RA, followed by lupus/LN and T1D. These studies will meticulously track patient responses to standard treatments while leveraging biomarkers to evaluate the relationship between sIL7R and patient outcomes.
With a robust design in place, the upcoming POC studies will juxtapose standard-of-care therapies against ABS's unique immuno-corrective approach. This methodological innovation parallels historical successes, such as GSK's pivotal trials for Benlysta, underlining the promising pathway ABS is charting in autoimmune care.
About Autoimmunity BioSolutions (ABS)
Autoimmunity BioSolutions (ABS) strives to pioneer personalized, genetically informed therapies aimed at correcting the heightened levels of soluble IL7 receptor (sIL7R). Recognizing the critical link between genetic variations and disease severity, ABS's approach positions it distinctively against traditional treatments that often depend on immunosuppressive tactics. This innovative perspective harbors significant promise for effectively managing a spectrum of autoimmune diseases.
Frequently Asked Questions
What is the main focus of Autoimmunity BioSolutions?
ABS focuses on developing personalized immuno-corrective therapies that normalize elevated soluble IL7 receptor levels in autoimmune disease patients.
Who are the newly appointed leaders at ABS?
The leadership team includes Richard Polisson as Chief Medical Officer and Jen Beachell as Chief Business Officer, among others.
Why is there a need for ABS's therapy?
Current treatments for autoimmune diseases show a high non-response rate, highlighting the demand for innovative therapies that target underlying genetic factors.
How does ABS plan to conduct its research?
ABS intends to execute bio-sample studies in autoimmune diseases, aiming to correlate genetic markers with treatment responses.
What differentiates ABS's therapy from others?
ABS's therapy targets specific genetic profiles associated with poor treatment responses, contrasting with the conventional immunosuppressive approach of standard therapies.
